Eli Lilly's Chief Financial Officer recently stated that its oral GLP-1 receptor agonist Orforglipron could enter the US market as early as the second quarter of this year, following expected regulatory approval in April.

This timeline has been confirmed by investment bank TD Cowen. If this pill formulation successfully enters the market, it will break through the current limitation of GLP-1 drugs requiring injection administration, providing a more convenient treatment option for diabetes and obesity patients. Market analysis points out that the oral formulation is expected to significantly improve drug accessibility and may further expand Eli Lilly's market advantage in the field of metabolic disease treatment.